Answers are grounded in this paper and cite their sources.
Botulinumtoxin injection into affected muscles is effective to improve motor symptoms of cervical dystonia by reducing muscle contraction and involuntary dystonic movement and posturing. However, the understanding of the effect on health-related quality of life (HR-QoL) and patient referral under HR-QoL aspects is incomplete. In this open-label clinical prospective observational study, we characterized the outcomes in cervical dystonia (n = 159) from botulinumtoxin on both generic HR-QoL (EuroQol; EQ-5D-5L) and disease-specific HR-QoL (CDQ-24). Additionally, we characterized motor and non-motor signs of dystonia including motor symptom improvement, depressive symptoms, pain and sleep quality. We assessed patients at the end of a regular three-month period from last injection (Timepoint1) and four weeks after the re-injection of BoNT (Timepoint2). We aimed to define outcomes on both generic and disease-specific HR-QoL and to evaluate predictors of therapeutic outcome in terms of stepwise multiple regression models. Patients with cervical dystonia showed a robust improvement of both generic and disease-specific HR-QoL. Furthermore, motor and non-motor signs improved. Multiple regression analyses revealed that EQ-5D-5L and ‘satisfaction with health’ (FLZ-G) at Timepoint1 predicted treatment response on generic HR-QoL outcome (R2 = 0.284; P = 0.019). Similarly, CDQ-24 and Beck’s Depression inventory at Timepoint1 predicted the treatment response on disease-specific HR-QoL (R2 = 0.253; P = 0.026). Our study underscores both generic and disease-specific HR-QoL improvements in cervical dystonia, and provides useful predictors on HR-QoL outcomes.
No takes yet. Share an insight, caveat, or question.
Weiß et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: